ABT-888 in Patients With Refractory Solid Tumors or Hematologic Cancer
Completed
National Cancer Institute (NCI)
Phase 1
RATIONALE: ABT-888 may stop the growth of cancer cells by blocking some of the enzymes needed
for cell growth. Collecting and storing samples of blood from patients with cancer to study
in the laboratory may help doctors learn more about the ways a patient's body handles the
drug.
PURPOSE: This early phase I trial is studying the side effects and best dose of ABT-888 in
patients with refractory solid tumors or hematologic cancer.
ABT-888 in Patients With Refractory Solid Tumors or Hematologic Cancer
Completed
National Institutes of Health Clinical Center (CC)
Phase 1
RATIONALE: ABT-888 may stop the growth of cancer cells by blocking some of the enzymes needed
for cell growth. Collecting and storing samples of blood from patients with cancer to study
in the laboratory may help doctors learn more about the ways a patient's body handles the
drug.
PURPOSE: This early phase I trial is studying the side effects and best dose of ABT-888 in
patients with refractory solid tumors or hematologic cancer.
Veliparib, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Cancer
Completed
National Cancer Institute (NCI)
Phase 1
This phase I trial is studying the side effects and best dose of veliparib when given
together with carboplatin and paclitaxel in treating patients with advanced solid cancer.
Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell
growth. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different
ways to stop the growth of tumor cells, either by killing the cells or by stopping them from
dividing. Giving veliparib together with carboplatin and paclitaxel may help kill more tumor
cells.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
